---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-22-000494"
form_type: "8-K"
ticker: "ALNY"
cik: "0001178670"
company_name: "ALNYLAM PHARMACEUTICALS, INC."
filed_at: "2022-04-28T23:59:59+00:00"
generated_at: "2026-06-26T03:11:17.426552+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Alnylam Q1 product revenue $187M, GAAP loss $240M; lowers 2022 guidance to $870-930M

## Summary
- Q1 total net product revenue $187M (+38% YoY); GAAP net loss $240M ($2.00 EPS), non-GAAP loss $180M ($1.49 EPS).
- Lowered 2022 combined revenue guidance to $870-930M from $900M-$1B due to Q1 pandemic impact and non-recurring Q4 2021 benefits.
- FDA extended vutrisiran NDA review to July 14, 2022; company expects launch upon approval if cleared.
- Patient growth: ONPATTRO >2,200 (+7%), GIVLAARI >400 (+14%), OXLUMO >160 (+14%) QoQ.
- Initiated Phase 1 for ALN-APP (Alzheimer's) and ALN-XDH (gout); filed patent suits against Pfizer/Moderna for COVID-19 vaccine lipids.

## SEC filing metadata
- accession: 0001157523-22-000494
- form_type: 8-K
- ticker: ALNY
- cik: 0001178670
- company_name: ALNYLAM PHARMACEUTICALS, INC.
- filed_at: 2022-04-28T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1178670/000115752322000494/0001157523-22-000494-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1178670/000115752322000494/a52699629.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-22-000494
- JSON: https://secwatch.observer/filing/0001157523-22-000494.json
- Plain text: https://secwatch.observer/filing/0001157523-22-000494.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.